Significant therapeutic advancement for patients with HER2-positive biliary tract cancer

At ESMO 2025, evolving treatment paradigms for biliary tract cancer (BTC) were presented at an oral session, highlighting the conditional approval of the first HER2-directed therapy for this patient population. While the treatment has generated considerable optimism, final regulatory approval remains dependent upon publication of additional confirmatory data.